Journal: International Journal of Molecular Sciences

Article Title: A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models †

doi: 10.3390/ijms252413627

Figure Lengend Snippet: Anti-tumor efficacy of CBA-1205 and lenvatinib in two different liver cancer cell xenograft mouse models. Human hepatocellular carcinoma cell lines (Hep3B, HepG2) were subcutaneously transplanted in the right flank of NOD-SCID mice. When the tumor volume reached >100 mm 3 , mice were randomized to treatment groups (eight animals in each group). Lenvatinib was orally administered 5 days a week. CBA-1205 was intraperitoneally administered approximately every 3 days. ( A ) Hep3B model groups received vehicle (purified water) or lenvatinib alone; ( B ) HepG2 model groups received vehicle or lenvatinib alone; ( C ) Hep3B model groups received vehicle, isotype control IgG1/κ, or CBA-1205 alone on days 14, 17, 21, and 24; ( D ) HepG2 model groups received vehicle, isotype control IgG1/κ, or CBA-1205 alone on days 10, 14, 17, 21, and 24. Data are shown as means ± SD. Error bars indicate ± SD. * p < 0.05, by the two-tailed Dunnett’s multiple comparison test using the vehicle control group as the reference group.

Article Snippet: Female NOD/ShiJic-scidJcl mice (NOD-SCID), 6–8 weeks old (Japan CLEA, Tokyo, Japan), were used in this study.

Techniques: Purification, Control, Two Tailed Test, Comparison

Journal: International Journal of Molecular Sciences

Article Title: A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models †

doi: 10.3390/ijms252413627

Figure Lengend Snippet: Combined effect of CBA-1205 and lenvatinib in liver cancer cell xenograft mouse models. ( A , B ) Human hepatocellular carcinoma cell lines (Hep3B, HepG2) were subcutaneously transplanted into the right flank of NOD-SCID mice. When the tumor volume reached >100 mm 3 , mice were randomized into dosing groups. CBA-1205 (0.3 and 1 mg/kg, twice a week, a total of four times) was administered intraperitoneally in combination with or without 3 mg/kg (for the Hep3B model) or 10 mg/kg (for the HepG2 model) of lenvatinib (daily, a total of 10 times) in mice (eight animals in each group). Vehicle was purified water for lenvatinib and phosphate-buffered saline for CBA-1205. Data are shown as means ± standard deviation (SD). Error bars indicate ± SD. * p < 0.05 by the two-tailed Dunnett’s multiple comparison test using the vehicle control group as the reference group.

Article Snippet: Female NOD/ShiJic-scidJcl mice (NOD-SCID), 6–8 weeks old (Japan CLEA, Tokyo, Japan), were used in this study.

Techniques: Purification, Saline, Standard Deviation, Two Tailed Test, Comparison, Control

Journal: Biotechnology and Bioengineering

Article Title: In vivo surveillance and elimination of teratoma‐forming human embryonic stem cells with monoclonal antibody 2448 targeting annexin A2

doi: 10.1002/bit.27135

Figure Lengend Snippet: In vivo elimination and suppression of teratoma formation via ADCC. Single‐cell suspension of hESCs was pretreated with ch2448 in vitro and injected into the right hind leg muscles of SCID mice ( n = 3). Killing via ADCC relied on the capacity of ch2448 to interact with the Fc receptors on the mouse effector cells in vivo. (a) Buffer control (b) hESC pretreated with ch2448. ADCC, antibody‐dependent cell‐mediated cytotoxicity; hESC, human embryonic stem cell; SCID, male severe combined immunodeficient

Article Snippet: Female NOD SCID mice (4–6‐week old) were purchased from InVivos.

Techniques: In Vivo, Suspension, In Vitro, Injection, Muscles, Control

Journal: Biotechnology and Bioengineering

Article Title: In vivo surveillance and elimination of teratoma‐forming human embryonic stem cells with monoclonal antibody 2448 targeting annexin A2

doi: 10.1002/bit.27135

Figure Lengend Snippet: Elimination and suppression of teratoma formation via ADC. Single‐cell suspension of hESCs was pretreated with (a) buffer, (b) anti‐Fab MMAE, (c) ch2448F(ab′) 2 and (d) ch2448F(ab′) 2 ‐MMAE in vitro and injected intramuscularly into the right hind leg of SCID mice ( n = 3). In another model, a single‐cell suspension of hESCs was first injected intramuscularly into the right hind leg of SCID mice ( n = 3). (e) Buffer and (f) ch2448F(ab′) 2 ‐MMAE administered intraperitoneally twice; on the day of cell injection and the following day. ADC, antibody‐drug conjugate; hESC, human embryonic stem cell; MMAE, monomethyl auristatin E; SCID, severe combined immunodeficient

Article Snippet: Female NOD SCID mice (4–6‐week old) were purchased from InVivos.

Techniques: Suspension, In Vitro, Injection